Full text is available at the source.
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
GLP-1 Receptor Drugs and Heart Disease: A Summary of Recent Heart Health Studies
AI simplified
Abstract
A total of 33,457 patients were included in the meta-analysis examining the cardioprotective effects of GLP-1 receptor agonists.
- GLP-1 receptor agonists significantly reduced all-cause mortality by 11% compared to placebo.
- Cardiovascular mortality was reduced by 12% with GLP-1 receptor agonists compared to placebo.
- Long-acting GLP-1 receptor agonists were associated with a 12% reduction in major adverse cardiac events.
- Non-fatal strokes decreased by 13% when patients were treated with long-acting GLP-1 receptor agonists.
- The cardioprotective effects may relate to improvements in metabolic parameters like glycemic control and weight loss.
AI simplified